OIPE
SEP 0 5 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M. M. Mjalli
Group Art Unit	1626
Examiner Name	[redacted] Stockton
Attorney Docket Number	41305-271622 (2001-07)
Express Mail Certificate	EV 032 108 785 US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
LRS	1	3,951,968		Claude P. Fauran et al.	04-20-76	
LRS	2	6,316,474		John A. McCauley et al.	11-13-01	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[5]
LRS	3	FR	2160719		Fauran	07-06-73		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
LRS	4	PCT Notification of Transmittal of the International Search Report corresponding to PCT application from PCT/US02/06706 ("Benzimidazole Derivatives as Therapeutic Agents") June 26, 2002	✓

Examiner Signature	Laura L. Stockton	Date Considered	8/27/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
SEP 0 9 2002
TECH CENTER 1600/2900

41305-271622
WINLIB01:966492.1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OIPE JUL 30 2002 PATENT & TRADEMARK OFFICE

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1626
Examiner Name	[redacted] Stockton
Attorney Docket Number	41305-271622 (2001-07)
Express Mail Certificate	EV 032 110 016 US

RECEIVED
AUG 06 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,166,452		Generales, Jr.	09-04-79	
	2	4,265,874		Bonsen, et al.	05-05-81	
	3	4,356,108		Schwab, et al.	10-26-82	
	4	4,873,313		Crawford, et al.	10-10-89	
	5	5,202,424		Vlassara, et al.	04-13-93	
	6	5,585,344		Vlassara, et al.	12-17-96	
	7	5,688,653		Ulrich, et al.	11-18-97	
	8	5,864,018		Morser, et al.	01-26-99	
	9	5,939,526		Gaugler, et al.	08-17-99	
	10	6,100,098		Newkirk	08-08-00	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[5]
	11	WO	00/20458		The Trustees of Columbia University in NYC	04-13-00		✓
	12	WO	00/20621		The Trustees of Columbia University in NYC	04-13-00		✓
	13	WO	97/26913		The Trustees of Columbia University in NYC	07-31-97		✓
	14	WO	97/39121		Schering Aktiengesellschaft	10-23-97		✓
	15	WO	9739125		Schering Aktiengesellschaft	10-23-97		✓
	16	WO	98/22138		The Trustees of Columbia University in NYC	05-28-98		✓
	17	WO	99/07402		The Trustees of Columbia University in NYC	02-18-99		✓
	18	WO	99/18987		The Trustees of Columbia University in NYC	04-22-99		✓
	19	WO	99/54485		The Trustees of Columbia University in NYC	10-28-99		✓
	20	WO	95/09838		Merrell Dow Pharmaceuticals Inc.	04-13-95		✓
	21	WO	95/35279		Merrell Pharmaceuticals Inc.	12-28-95		✓
	22	WO	97/22618		Vertex Pharmaceuticals Incorporated	06-26-97		✓
	23	WO	96/32385		Hoechst Marion Roussel Inc.	10-17-96		✓
	24	WO	99/50230		Vertex Pharmaceuticals Incorporated	10-07-99		✓

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OIPE JUL 30 2002 PATENT & TRADEMARK OFFICE

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1626
Examiner Name	~~Unassigned~~ Stockton
Attorney Docket Number	41305-271622 (2001-07)
Express Mail Certificate	EV 032 110 016 US

RECEIVED
AUG 0 6 2002
TECH CENTER 1600/2900

	25	GB	2 005 674			Carlo Erba S.p.A.		04-25-79		✓
	26	WO	98/33492			Fox Chase Cancer Center		08-06-98		✓
	27	WO	99/25690			University of Kansas Medical Center		05-27-99		✓
	29	WO	01/12598			Trustees of Columbia Univ. in NYC		02-22-01		✓

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	29	Albercio, F. & Carpino, L.A., "Coupling Reagents and Activation" *Methods in Enzymology* 289:104-126, Academic Press, San Diego **(1997)**	✓
	30	Barton, J.W., " In Protection of N-H Bonds and NR_3" *Protective Groups in Organic Chemistry,* J.F.W. McOmie, ED., Plenum Press, New York, NY **(1973)**	✓
	31	Berge, S.M., et al., "Pharmaceutical Salts" *Journal of Pharmaceutical Sciences* 66:1-19 **(1977)**	✓
	32	Chitaley, K., et al., "Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway" *Nature Medicine* 7:119-122 **(2002)**	✓
	33	Degenhardt, T.P., et al., "Chemical Modification of Proteins by Methylglyoxal" *Cell Mol. Biol.*, 44:1139-1145 **(1998)**	✓
	34	Dyer, D.G., et al., "Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging" *J. Clin. Invest.*, 91:2463-2469 **(1993)**	✓
	35	Dyer, D.G., et al., "Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose" *J. Biol. Chem.*, 266:11654-11660 **(1991)**	✓
	36	Greene, T.W.," Protection for the Amino Group" *Protective Groups in Organic Synthesis,* John Wiley and Sons, New York, NY, Chapter 7 **(1981)**	✓
	37	Hammes, H.P., et al., "Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product N^{ϵ}-(Carboxymethyl) Lysine Independently of Glycohaemoglobin Concentrations" Diabetologia, 42:603-607 **(1999)**	✓
	38	Hoffman, M.A., et al., "RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides" *Cell*, 97:889-901 **(1999)**	✓
	39	Hori, O., et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding site for Amphoterin" *J. Biol. Chem.*, 270:25752-761 **(1995)**	✓
	40	Huttunen, H.J., et al., "Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways" *J. Biol. Chem.* 274(28):19919-24 **(1999)**	✓
	41	Kumar, S.R., et al., "RAGE at th Blood-Brain Barrier Mediates Neurovascular Dysfunction Caus d by Amyloidβ_{1-40} Peptide" *Neurosci. Program*, 141-#255.19 **(2000)**	✓

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED
AUG 06 2002
TECH CENTER 1600/2900

OIPE JUL 30 2002 PATENT & TRADEMARK OFFICE

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1626
Examiner Name	~~Unassigned~~ Stockton
Attorney Docket Number	41305-271622 (2001-07)
Express Mail Certificate	EV 032 110 016 US

	42	Leder, A. et al., "v-HA-*ras* Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid" *Proc. Natl. Acad. Sci., USA*, 87:9178-9182 **(1990)**	✓
	43	Li, J. et al., "Sp1-Binding elements in the Promoter of RAG Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells." *J. Biol. Chem.*, 273:30870-30878 **(1998)**	✓
	44	Li, J. et al., "Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products," *J. Biol. Chem.*, 272:16498-16506 **(1997)**	✓
	45	Lugering, N. et al., "The Myeloic Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function" Eur. J. Clin. Invest., 25:659-664 **(1995)**	✓
	46	Miyata, T. et al., "β_2-Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis" *J. Clin. Invest.*, 92:1243-1252 **(1993)**	✓
	47	Miyata, T. et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE-β_2Microglobulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway" *J. Clin. Invest.*, 98:1088-1094 **(1996)**	✓
	48	Neeper, M., et al., "Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins" *J. Biol. Chem.*, 267:14998-15004 **(1992)**	✓
	49	Parkkinen, J. et al., "Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides" *J. Biol Chem.*, 268:19726-19738 **(1993)**	✓
	50	Rammes, A. et al., "Myeloid-Related Protein (MRP) 8 and MRP 14, Calcium-Binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-Dependent Pathway *J. Biol. Chem.*, 272:9496-9502 **(1997)**	✓
	51	Rauvala, H. et al., "Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons" *J. Biol. Chem.*, 262:16625-16635 **(1987)**	✓
	52	Reddy, S. et al., "N^{ε}-(Carboxymethyl) Lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins" *Biochem.*, 34:10872-10878 **(1995)**	✓
	53	Schafer, B.W., et al., "The S100 Family of EF-Hand Calcium-Binding Proteins: Functions and Pathology" *TIBS*, 21:134-140 **(1996)**	✓
	54	Schleicher, E.D., et al., "Increased Accumulation of the Glycoxidation Product N^{ε}-(Carboxymethyl) Lysine in Human Tissues in Diabetes and Aging" *J. Clin. Invest.*, 99(3):457-468 **(1997)**	✓
	55	Schmidt, A.M. et al., "The Dark Side of Glucose" *Nature Med.*, 1:1002-1004 **(1995)**	✓
	56	Schmidt, A.M., et al., "The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications:" *Supplement to Circulation* Vol. 96, #194 **(1997)**	✓
	57	Taguchi, A. et al., "Blockade f RAGE—Amphot rin Signalling Suppresses Tumour Growth and Metastases" *Nature*, 405:354-360 **(2000)**	✓

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

JUL 30 2002 PATENT & TRADEMARK OFFICE

RECEIVED
AUG 06 2002
TECH CENTER 1600/2900

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1626
Examiner Name	~~Unassigned~~ Stockton
Attorney Docket Number	41305-271622 (2001-07)
Express Mail Certificate	EV 032 110 016 US

	58	Tanaka, N., et al., "The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradoil through Sp-1 in Human Vascular Endothelial Cells" *J. Biol. Chem.*, 275:25781-25790 **(2000)**	✓
	59	Teillet et al., "Food Restriction Prevents Advanced Glycation End Product Accumulation and Retards Kidney Aging in Lean Rats" *J. Am. Soc. Nephrol.*, 11:1488-1497 **(2000)**	✓
	60	Vlassara, H., "Advanced Glycation End-Products and Atherosclerosis" *The Finnish Medical Society DUODECIM, Ann. Med.*, 28:419-426 **(1996)**	✓
	61	Wautier et al., "Receptor-Mediated Endothelial Cell Dysfunction in Diabetic Vasculopathy: Soluble Receptor for Advanced Glycation End Products Blocks Hyperpermeability in Diabetic Rats" *J. Clin. Invest.*, 97:238-243 **(1996)**	✓
	62	Yan, S.-D., et al., "RAGE and Amyloid-β Peptide Neurotoxicity in Alzheimer's Disease" *Nature* 382:685-691 **(1996)**	✓
	63	Yan, S.-D., et al., "An Intracellular Protein That Binds Amyloid-β Peptide and Mediates Neurotoxicity in Alzheimer's Disease" *Nature*, 389:689-695, **(1997)**	✓
	64	Yan, S.-D. et al., "Amyloid-β Peptide—Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease" *Proc. Natl. Acad. Sci., USA*, 94:5296-5301 **(1997)**	✓
	65	Yan, S.-D. et al., "Receptor-Dependent Cell Stress and Amyloid Accumulation in Systemic Amyloidosis" *Nat. Med.* 6:643-651 **(2000)**	✓
	66	Yan, S.-D. et al., "Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation Endproducts With Their Receptors Binding Proteins" J. Biol. Chem. 269:9889-9897 **(1994)**	✓
	67	Zimmer, D. et al., The S100 Protein Family: History, Function, and Expression" *Brain Res. Bull*, 37:417-429 **(1995)**	✓
	68	International Search Report for PCT/US 01/17251 dated 8/14/01	✓

Examiner Signature	Laura L. Stockton	Date Considered	8/27/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

41305-252461
WINLIB01:956770.1